14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SANA vs CCCC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CCCC Captures Overall Composite Edge (57.2 HOLD vs 44.3 HOLD), While SANA Leads 3–2 on Growth & Valuation Pillars
CCCC Overall Winner
6-Pillar Tally: SANA 3 – 2 CCCC (1 Tie)
Matrix Metrics: SANA 4 – 4 CCCC
As of Nov 16, 2026, C4 Therapeutics, Inc. (CCCC) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (57.2/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.65 (N/M Forward P/E, -315.9% operating margin).
Growth vs. Quality Trade-Off: CCCC earns the overall head-to-head edge with a stronger Unified Composite Score (57.2/100 HOLD vs. SANA 44.3/100 HOLD) and 1.46β · 69% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs CCCC. Trailing 12-month operating profitability (SANA 0.0% vs CCCC -315.9%) and valuation multiples (SANA N/M vs CCCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $363.7M market capitalization and -315.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SANA vs CCCC Key Questions & Quantitative Answers
As of Nov 16, 2026, C4 Therapeutics, Inc. (CCCC) captures the overall head-to-head institutional edge over Sana Biotechnology, Inc. (SANA) on higher Unified Composite conviction (57.2/100 HOLD vs. 44.3/100 HOLD) after splitting the core matrix 4–4 (led by Valuation Multiples, Options & Positioning), while SANA wins 3–2 across the 6-pillar growth and valuation breakdown. SANA trades at $1.88 (N/M Forward P/E, 0.0% operating margin) versus CCCC at $2.65 (N/M Forward P/E, -315.9% operating margin). Growth vs. Quality Trade-Off: CCCC earns the overall head-to-head edge with a stronger Unified Composite Score (57.2/100 HOLD vs. SANA 44.3/100 HOLD) and 1.46β · 69% Vol risk profile, whereas SANA leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CCCC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SANA leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CCCC at -24.6% YoY revenue growth and +0.0% YoY earnings growth on $32M TTM revenue (88.8% gross margin, -315.9% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $32M for CCCC. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CCCC.
CCCC screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CCCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 12.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus CCCC (-47.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SANA carries 222.6% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, CCCC carries 79.8% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.46β · 69% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.